In SPMS patients, RNA derived from whole-blood samples of siponimod-treated patients have reduced expression levels of immune-associated genes involved in T- and B-cell activation and receptor signaling, which is consistent with the reduction in CD4+ T cells, CD8+ T cells, and B cells. This evidence concerns the gene CD8A and secondary progressive multiple sclerosis.